Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Gilead

HCV Franchise takes a hit, down 59% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead
1Q Revenues: $5.1 billion (-22%)
1Q Earnings: $1.5 billion (-43%)
Comments: Antiviral product sales, which include sales of HIV, chronic hepatitis B (HBV) and chronic hepatitis C (HCV) products, were $4.4 billion in the quarter, down 24%. HIV and HBV product sales were $3.3 billion, up 2% primarily due to the continued uptake of tenofovir alafenamide (TAF)-based products, which include Genvoya, Descovy and Odefsey. HCV product sales, which consist of Epclusa, Harvoni, Vosevi and Sovaldi, were $1.0 billion, down 59% primarily due to lower sales of Harvoni and Sovaldi across all major markets and lower sales of Epclusa in the U.S. as a result of increased competition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters